Filter articles using the following links

GenSight Biologics Announces Publication of Meta-Analysis Confirming that Spontaneous Recovery in LHON is rare in the Journal of Neuro-Ophthalmology

GenSight Biologics reports new analysis demonstrating statistically significant and clinically meaningful difference between visual outcomes in LUMEVOQ®-treated patients and natural history of Leber Hereditary Optic Neuropathy (LHON)

GenSight Biologics Submits EU Marketing Authorisation Application for LUMEVOQ® Gene Therapy to Treat Vision Loss due to Leber Hereditary Optic Neuropathy (LHON)

H.C. Wainwright 22nd Annual Global Investment Conference – Virtual Conference

OIS Retina Innovation Showcase

GenSight Biologics draws down the €4 million second tranche of bonds from Kreos Capital

UMDF Power Surge 2020 – online event

2020 Annual Scientific Meeting ASRS – Virtual format

GenSight Biologics Reports Interim Financial Results for the First Half of 2020 and Provides Operational Update

GenSight Biologics reports final REALITY natural history study results confirming poor spontaneous recovery for LHON patients with ND4 mutation